within Pharmacolibrary.Drugs.N_NervousSystem.N06B_PsychostimulantsAgentsUsedForAdhdAndNootropics.N06BA11_Dexmethylphenidate;

model Dexmethylphenidate
  extends Pharmacolibrary.Drugs.ATC.N.N06BA11;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>N06BA11</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Dexmethylphenidate is the d-threo-enantiomer of methylphenidate, a central nervous system stimulant used in the treatment of attention-deficit hyperactivity disorder (ADHD) in children and adults. It is approved and commonly prescribed for ADHD management due to its efficacy and tolerability.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in healthy adult subjects after single-dose oral administration of immediate-release dexmethylphenidate tablets.</p><h4>References</h4><ol><li><p>Spencer, TJ, et al., &amp; Fischman, AJ (2012). Understanding the central pharmacokinetics of spheroidal oral drug absorption system (SODAS) dexmethylphenidate: a positron emission tomography study of dopamine transporter receptor occupancy measured with C-11 altropane. <i>The Journal of clinical psychiatry</i> 73(3) 346–352. DOI:<a href=&quot;https://doi.org/10.4088/JCP.10m06393&quot;>10.4088/JCP.10m06393</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/22154896/&quot;>https://pubmed.ncbi.nlm.nih.gov/22154896</a></p></li><li><p>Braeckman, R, et al., &amp; Oh, C (2022). Dose Proportionality and Steady-State Pharmacokinetics of Serdexmethylphenidate/Dexmethylphenidate, a Novel Prodrug Combination to Treat Attention-Deficit/Hyperactivity Disorder. <i>Journal of child and adolescent psychopharmacology</i> 32(5) 288–295. DOI:<a href=&quot;https://doi.org/10.1089/cap.2022.0015&quot;>10.1089/cap.2022.0015</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/35666231/&quot;>https://pubmed.ncbi.nlm.nih.gov/35666231</a></p></li><li><p>McGough, JJ, et al., &amp; Suddath, R (2005). Dexmethylphenidate extended-release capsules for attention deficit hyperactivity disorder. <i>Expert review of neurotherapeutics</i> 5(4) 437–441. DOI:<a href=&quot;https://doi.org/10.1586/14737175.5.4.437&quot;>10.1586/14737175.5.4.437</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/16026226/&quot;>https://pubmed.ncbi.nlm.nih.gov/16026226</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end Dexmethylphenidate;
